The single most consequential question in GLP-1 telehealth is one many patients never think to ask: am I receiving an FDA-approved medicine made by Novo Nordisk or Eli Lilly, or a compounded preparation made by a pharmacy? The active ingredient may share a name, but the regulatory status, oversight, supply chain, and price are entirely different. This guide explains the distinction, why it matters, and what to ask before you buy.

Quick Takeaway:

• Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) are FDA-approved finished medicines with full regulatory oversight
• Compounded GLP-1s are prepared by compounding pharmacies and are not FDA-approved products
• Compounded preparations are not reviewed by the FDA for safety, efficacy, or quality before they are marketed
• Compounding pharmacies fall into two categories — 503A and 503B — with meaningfully different oversight
• Manufacturer self-pay channels have narrowed the price gap considerably since 2025

Looking for a Better Alternative?

Whichever route you choose, provider quality determines your experience. CoreAge Rx is our top-rated favorite for GLP-1 weight loss therapy, combining competitive pricing with exceptional customer service, faster medication delivery, and more comprehensive support resources.

Why we recommend CoreAge Rx:

• Lower monthly costs than most competitors ($179–$399 range)
• Faster prescription approval (typically 12–24 hours)
• More extensive provider support included at no extra charge
• Better medication availability during shortages
• Higher patient satisfaction scores (4.7/5)

New Patient Special: Save up to $200 on your first three months. Same-day prescription approval for qualifying patients. Rated 4.7/5 stars by verified customers. No insurance required.

What "Brand-Name" Actually Means

An FDA-approved medicine has been through a defined regulatory process: preclinical work, clinical trials establishing safety and efficacy, and manufacturing review covering facility standards, batch consistency, purity, potency, stability, labelling, and post-marketing surveillance. Every vial or pen of Wegovy or Zepbound is produced under that regime.

That is what you are buying when you fill a prescription at a pharmacy or through LillyDirect or NovoCare Pharmacy. It is also why these products cost what they cost.

What "Compounded" Actually Means

Compounding is the practice of a licensed pharmacy preparing a medication for a patient — traditionally to meet a need the commercial product cannot, such as an allergy to an inactive ingredient or a dose strength not manufactured.

Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they reach patients. That is not a loophole; it is the defined legal status of compounded preparations, and it is why the FDA publishes specific cautions about compounded GLP-1 products.

Compounding pharmacies fall into two categories under US law:

A 503B outsourcing facility operates under considerably more oversight than a 503A pharmacy. It is not equivalent to FDA approval of the product, but it is a meaningful quality signal. Empower Pharmacy, for example, is an FDA-registered 503B facility supplying GLP-1 telehealth providers.

Important: Ask your provider two specific questions: which pharmacy fills my prescription, and is it a 503A or 503B facility? A provider that cannot or will not answer clearly is telling you something important.

Why Compounded GLP-1s Became Widespread

Between 2023 and 2025, semaglutide and tirzepatide were in declared shortage. Under US law, shortage status permits compounding of drugs that would otherwise be off-limits because they copy an approved product. An entire cash-pay telehealth industry grew in that window, offering compounded semaglutide and tirzepatide at prices far below branded list prices of $1,000 or more per month.

As shortages resolved and manufacturers launched direct self-pay channels at $349–$699 per month, that price gap narrowed sharply — and several major platforms, including Ro and Hims & Hers, moved away from compounded GLP-1s toward FDA-approved product. The economic case for compounding is weaker now than it was in 2024, though compounded programmes still typically undercut branded pricing.

The Real Risks of Compounded Preparations

These are not theoretical concerns, and they are worth stating plainly:

1. Potency variability. Without batch-level regulatory verification, the actual concentration in a vial may differ from the label.
2. Dosing errors. Compounded products are often supplied in multi-dose vials requiring the patient to draw up a dose, rather than a pre-set pen. Dosing errors — including tenfold overdoses from unit confusion — have been reported to poison control centres.
3. Salt forms. Some compounded products have used semaglutide salt forms (sodium or acetate) which are not the active ingredient in approved medicines and have not been shown to be safe and effective.
4. Sourcing. Active pharmaceutical ingredient may originate from facilities not subject to the same oversight.
5. Shorter beyond-use dating. Compounded preparations have shorter stability windows than manufacturer product and must be used within the assigned date.
6. No manufacturer support. No patient assistance programme, no manufacturer adverse event system, and limited recourse if something goes wrong.

The Honest Case for Compounded Products

It would be dishonest to present only one side. Compounded GLP-1s have made treatment accessible to a large number of people who could not otherwise afford it, dispensed by licensed pharmacies under state regulation and prescribed by licensed clinicians. Many patients have had good outcomes and no adverse events.

The reasonable position is not that compounded products are inherently dangerous, but that they carry a category of risk that FDA-approved products do not — and that you should make that trade-off knowingly rather than by accident.

Cost Comparison

The cheapest legitimate route for most insured patients is their own pharmacy benefit. See our insurance, HSA and FSA guide.

Questions to Ask Any Provider

1. Is the medication I will receive FDA-approved, or compounded?
2. Which pharmacy dispenses it, and is it a 503A or 503B facility?
3. Will I receive a pre-filled pen or a vial I draw from myself?
4. What is the beyond-use date, and how should I store it?
5. What is the exact dose in milligrams, and in what volume?
6. What happens if I have an adverse reaction — who do I contact?

Frequently Asked Questions

Are compounded GLP-1 medications FDA-approved?

No. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before they are marketed. This is their defined legal status, not a technicality.

Is compounded semaglutide the same as Wegovy?

It contains a substance described as semaglutide, but it is not the same product. Wegovy is a finished FDA-approved medicine manufactured under regulated conditions with verified potency, purity, and stability. A compounded preparation has none of those regulatory guarantees, and some compounded products have used salt forms that are not the active ingredient in approved medicines.

What is the difference between a 503A and a 503B pharmacy?

A 503B outsourcing facility registers with the FDA, must follow current good manufacturing practice standards, and is subject to routine FDA inspection. A 503A pharmacy compounds against individual prescriptions and is not held to those manufacturing standards or routine federal inspection.

Is compounded medication legal?

Compounding by licensed pharmacies is legal under defined circumstances. Compounding copies of commercially available approved drugs is generally restricted, with shortage status having created the conditions for widespread GLP-1 compounding between 2023 and 2025.

Why is compounded medication cheaper?

It does not carry the costs of drug development, clinical trials, regulatory approval, and branded distribution. It also does not carry the corresponding assurances.

Should I switch from compounded to brand-name?

That is a decision for you and your prescriber, but the calculation has changed. Manufacturer self-pay channels at $349–$699 per month have substantially narrowed the gap that made compounding compelling. If the difference is now modest for your dose, FDA-approved product removes an entire class of risk.

Bottom Line

The distinction between compounded and brand-name GLP-1 medication is the most important thing to understand before choosing a provider, and it is systematically underexplained in telehealth marketing.

Brand-name products carry full regulatory oversight and cost more. Compounded products cost less and carry risks around potency, dosing, sourcing, and recourse that approved medicines do not. Since manufacturer direct channels launched at $349–$699 per month, the price argument for compounding has weakened considerably.

Ask which product you are getting. Ask which pharmacy makes it. Then decide deliberately.

CoreAge Rx: all-in monthly pricing from $179–$399 with provider messaging and titration support included, and 12–24 hour approvals. Confirm medication type directly with any provider before enrolling.

Medical disclaimer: Informational only, not medical advice. GLP-1 receptor agonists are prescription medicines with real risks and contraindications. Compounded medications are not FDA-approved. Consult a qualified healthcare professional before starting or changing treatment.

Sources: FDA guidance on human drug compounding and cautions regarding compounded GLP-1 products; FDA prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro; LillyDirect and NovoCare® published self-pay pricing.

Date reviewed: August 2026